Ginkgo Bioworks Holdings Stock Fundamentals
| DNA Stock | USD 7.59 0.32 4.40% |
Ginkgo Bioworks Holdings fundamentals help investors to digest information that contributes to Ginkgo Bioworks' financial success or failures. It also enables traders to predict the movement of Ginkgo Stock. The fundamental analysis module provides a way to measure Ginkgo Bioworks' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ginkgo Bioworks stock.
At present, Ginkgo Bioworks' Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 1.3 B, whereas Tax Provision is forecasted to decline to (502.9 K).
Ginkgo | Select Account or Indicator |
Ginkgo Bioworks Holdings Company Operating Margin Analysis
Ginkgo Bioworks' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Ginkgo Bioworks Operating Margin | (2.15) % |
Most of Ginkgo Bioworks' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ginkgo Bioworks Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Ginkgo Pretax Profit Margin
Pretax Profit Margin |
|
At present, Ginkgo Bioworks' Pretax Profit Margin is projected to slightly decrease based on the last few years of reporting.
Based on the recorded statements, Ginkgo Bioworks Holdings has an Operating Margin of -2.1469%. This is 93.88% lower than that of the Biotechnology sector and 98.08% lower than that of the Health Care industry. The operating margin for all United States stocks is 61.04% lower than that of the firm.
Ginkgo Bioworks Holdings Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ginkgo Bioworks's current stock value. Our valuation model uses many indicators to compare Ginkgo Bioworks value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ginkgo Bioworks competition to find correlations between indicators driving Ginkgo Bioworks's intrinsic value. More Info.Ginkgo Bioworks Holdings is rated # 2 in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers . At present, Ginkgo Bioworks' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ginkgo Bioworks' earnings, one of the primary drivers of an investment's value.Did you try this?
Run CEOs Directory Now
Ginkgo Bioworks ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ginkgo Bioworks' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ginkgo Bioworks' managers, analysts, and investors.Environmental | Governance | Social |
Ginkgo Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (2.41) % | ||||
| Operating Margin | (2.15) % | ||||
| Current Valuation | 328.06 M | ||||
| Shares Outstanding | 45.81 M | ||||
| Shares Owned By Insiders | 6.59 % | ||||
| Shares Owned By Institutions | 79.85 % | ||||
| Number Of Shares Shorted | 9.06 M | ||||
| Price To Earning | 25.51 X | ||||
| Price To Book | 0.59 X | ||||
| Price To Sales | 1.86 X | ||||
| Revenue | 227.04 M | ||||
| Gross Profit | 182.5 M | ||||
| EBITDA | (484.39 M) | ||||
| Net Income | (547.03 M) | ||||
| Cash And Equivalents | 1.32 B | ||||
| Cash Per Share | 0.84 X | ||||
| Total Debt | 438.77 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 11.84 X | ||||
| Book Value Per Share | 13.17 X | ||||
| Cash Flow From Operations | (319.58 M) | ||||
| Short Ratio | 4.28 X | ||||
| Earnings Per Share | (10.54) X | ||||
| Target Price | 8.6 | ||||
| Number Of Employees | 834 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 421.9 M | ||||
| Total Asset | 1.38 B | ||||
| Retained Earnings | (5.84 B) | ||||
| Working Capital | 495.48 M | ||||
| Current Asset | 10.07 B | ||||
| Current Liabilities | 3.1 B | ||||
| Net Asset | 1.38 B |
About Ginkgo Bioworks Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ginkgo Bioworks Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ginkgo Bioworks using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ginkgo Bioworks Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 27.7 M | 40.9 M | |
| Total Revenue | 227 M | 256.8 M | |
| Cost Of Revenue | 38.5 M | 36.6 M | |
| Stock Based Compensation To Revenue | 0.49 | 0.47 | |
| Sales General And Administrative To Revenue | 1.08 | 1.17 | |
| Research And Ddevelopement To Revenue | 1.87 | 1.70 | |
| Capex To Revenue | 0.28 | 0.35 | |
| Revenue Per Share | 4.38 | 4.30 | |
| Ebit Per Revenue | (2.47) | (2.59) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Ginkgo Bioworks Piotroski F Score and Ginkgo Bioworks Altman Z Score analysis. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. If investors know Ginkgo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ginkgo Bioworks listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.54) | Revenue Per Share | Quarterly Revenue Growth 0.262 | Return On Assets | Return On Equity |
The market value of Ginkgo Bioworks Holdings is measured differently than its book value, which is the value of Ginkgo that is recorded on the company's balance sheet. Investors also form their own opinion of Ginkgo Bioworks' value that differs from its market value or its book value, called intrinsic value, which is Ginkgo Bioworks' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ginkgo Bioworks' market value can be influenced by many factors that don't directly affect Ginkgo Bioworks' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ginkgo Bioworks' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ginkgo Bioworks is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ginkgo Bioworks' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.